Lynk Pharmaceuticals patents new GTPase KRAS mutant inhibitors for cancer

July 26, 2023

Lynk Pharmaceuticals Co. Ltd. has disclosed nitrogen-containing heterocyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

BioWorld Science Cancer Patents

Today's news in brief

BioWorld

BioWorld briefs for Dec. 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

Businesspeople shaking hands, meeting with cityscape, charts

Deals and an M&A strengthen end-of-year numbers

BioWorld

Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...

Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints

BioWorld

Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...